Benzinga | Jul 12, 2021 03:16PM EDT

Heart Disease Company Tenaya Therapeutics Files For $100M US IPO

* Tenaya Therapeutics (NASDAQ:TNYA) is quickstepping into a $100 million NASDAQ debut under the TNYA symbol. The company filed an SEC prospectus on Friday.

* The biotech firm is attacking heart disease through three different angles - gene therapy, cellular regeneration, and precision medicine.

* Its $106 million series C, pulled off back in March, was designed to help propel several preclinical programs toward the clinic, including gene therapy for hypertrophic cardiomyopathy (HCM) and set up a site in the Bay Area to manufacture vectors.

* Tenaya is starting with an AAV-based gene therapy targeting mutations in the MYBPC3 gene, the leading genetic cause of HCM.

* According to its SEC-1 filing, it plans INDs for its gene therapy and precision medicine platforms in 2022.

* In addition to VC backers The Column Group and Casdin Capital, Tenaya's key shareholders include Walmart heir Thomas Walton.